Cybrexa Therapeutics
Per Hellsund has held various leadership roles throughout their career. Per is currently the President & CEO of Cybrexa Therapeutics, a company focused on developing small molecule DNA repair inhibitors. Prior to this, they were the President & CEO of CyOmics, where they worked to develop and commercialize products in the Life Sciences and Diagnostics field. Per also served as President & CEO of CyVek, inc.jet, Inc., and Gunther International, where they held various executive positions.
Per Hellsund has obtained a Master of Science in Management from Rensselaer Polytechnic Institute. No further information is available regarding their education history, such as specific dates or other degrees.
Cybrexa Therapeutics
1 followers
Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and itwill greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.